[{"data":1,"prerenderedAt":165},["ShallowReactive",2],{"drug-mercaptopurine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":35,"contraindications":64,"warnings":65,"renal":73,"monitoring":74,"interactions":75,"review":76,"examples":79,"atc":86,"iran":88,"usApproval":100,"links":106,"populations":122},"mercaptopurine",1,{"fa":7,"en":8},"مرکاپتوپورین","Mercaptopurine","antineoplastic-immunomodulating",{"fa":11,"en":12},"آنتی‌متابولیت پورین","Purine antimetabolite",[14],{"name":15,"market":16},"Purixan","US",[18,19,20,7],"purinethol","purixan","6-MP",[22],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":30,"refs":31},"susp-20","suspension","oral","20 mg\u002FmL oral suspension",{"amount":28,"unit":29,"perVolumeMl":5},20,"mg",[16],[32],{"source":33,"section":34},"fda-mercaptopurine","3",[36],{"id":37,"disease":38,"label":39,"population":42,"type":43,"unit":29,"dose":44,"refs":48,"notes":51},"all","acute-lymphoblastic-leukemia",{"fa":40,"en":41},"ALL — نگهدارنده در رژیم ترکیبی: ۱٫۵ تا ۲٫۵ mg\u002Fkg یک بار در روز","ALL — combination maintenance: 1.5–2.5 mg\u002Fkg once daily",{},"weightBased",{"perKgPerDose":45,"perKgPerDoseMax":46,"intervalHours":47},1.5,2.5,24,[49],{"source":33,"section":50},"2.1",[52],{"text":53,"refs":56},{"fa":54,"en":55},"معادل ۵۰ تا ۷۵ mg\u002Fm². تنظیم با ANC. کمبود TPMT\u002FNUDT15 هموزیگوت: ۱۰٪ یا کمتر. با آلوپورینول یک‌سوم تا یک‌چهارم. ClCr زیر ۵۰ یا نارسایی کبد: کمترین دوز یا فاصله ۳۶ تا ۴۸ ساعت.","Equals 50–75 mg\u002Fm². Adjust to ANC. Homozygous TPMT\u002FNUDT15 deficiency: ≤10%. With allopurinol one-third to one-quarter. CrCl \u003C50 or hepatic impairment: lowest dose or every 36–48 h.",[57,58,60,62],{"source":33,"section":50},{"source":33,"section":59},"2.2",{"source":33,"section":61},"2.4",{"source":33,"section":63},"2.3",[],[66],{"text":67,"refs":70},{"fa":68,"en":69},"سرکوب مغز استخوان؛ سمیت کبدی؛ سرکوب ایمنی؛ بدخیمی ثانویه؛ سندرم فعال شدن ماکروفاژ؛ سمیت جنینی.","Myelosuppression; hepatotoxicity; immunosuppression; secondary malignancy; macrophage activation syndrome; embryo-fetal toxicity.",[71],{"source":33,"section":72},"5",[],[],[],{"status":77,"reviewer":78,"date":78},"unverified",null,[80],{"regimen":37,"formulation":23,"input":81,"expect":83},{"ageYears":82,"weightKg":28},6,{"perDose":84,"mlPerDose":45,"upperPerDose":85},30,50,[87],"L01BB02",{"status":89,"forms":90,"refs":95},"registered",[91],{"code":92,"en":93,"fa":94},"00811","MERCAPTOPURINE 50MG TAB","قرص مرکاپتوپورین ۵۰ میلی‌گرم",[96],{"source":97,"section":98,"url":99},"darooyab-generic","G-1027\u002FMercaptopurine","https:\u002F\u002Fwww.darooyab.ir\u002FG-1027\u002FMercaptopurine",{"kind":101,"refs":102,"id":105},"ANDA",[103],{"source":33,"section":104},"SPL approval \u002F marketing category","ANDA216418",[107,110,114,117,120],{"kind":108,"url":109,"label":105},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=216418",{"kind":111,"url":112,"label":113},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=0a366cf3-91f0-4aa4-8f34-a7a27cad8f15","FDA Mercaptopurine susp",{"kind":115,"url":116,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682653.html",{"kind":118,"url":119,"label":87},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L01BB02",{"kind":121,"url":99,"label":8},"darooyab",{"pregnancy":123,"lactation":132,"pediatric":140,"geriatric":149,"reproductive":157},{"level":124,"text":125,"quote":128,"refs":129},"avoid",{"fa":126,"en":127},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","Risk Summary Mercaptopurine can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] .",[130],{"source":33,"section":131},"8.1",{"level":124,"text":133,"quote":136,"refs":137},{"fa":134,"en":135},"برچسب: شیردهی توصیه نمی‌شود یا باید بین دارو و شیردهی یکی انتخاب شود.","Label: breastfeeding not recommended, or choose between the drug and breastfeeding.","Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with mercaptopurine and for 1 week after the last dose.",[138],{"source":33,"section":139},"8.2",{"level":141,"text":142,"quote":145,"refs":146},"caution",{"fa":143,"en":144},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","Safety and effectiveness of mercaptopurine have been established in pediatric patients.",[147],{"source":33,"section":148},"8.4",{"level":141,"text":150,"quote":153,"refs":154},{"fa":151,"en":152},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy.",[155],{"source":33,"section":156},"8.5",{"level":141,"text":158,"quote":161,"refs":162},{"fa":159,"en":160},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Females Advise females of reproductive potential to use effective contraception during treatment with mercaptopurine and for 6 months after the last dose.",[163],{"source":33,"section":164},"8.3",1792444410159]